Alimera Reports 36-Month Results From Phase 3 FAME Study

The completed 36-month results of the phase 3 FAME study of low-dose Iluvien (fluocinolone acetonide; Alimera Sciences) show statistically significant improvements in vision in patients with diabetic macular edema, according to a company news release. Iluvien is an intravitreal insert for the sustained delivery of fluoci...